Insulin degludec/insulin aspart is the first co-formulation of basal and prandial insulin analogues
Achievement of glycemic control is the major therapeutic aim to prevent or delay the onset and progression of diabetes related complications. Insulin therapy represents a cornerstone in the treatment of diabetes and has been used widely for achieving glycemic goals. The aim for insulin therapy is to...
Saved in:
| Main Authors: | Ivan Ivanovich Dedov, Marina Vladimirovna Shestakova |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2014-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Continuous Glucose Monitoring and Hypoglycaemia Metrics With Once‐Weekly Basal Insulin Fc Versus Insulin Degludec: A Systematic Review and Meta‐Analysis
by: Saaed Abunada, et al.
Published: (2025-07-01) -
Switching to insulin degludec/aspart penfill reusable cartridges in patients with type 2 diabetes mellitus: real-life outcomes
by: Sezin Dogan Çakır, et al.
Published: (2025-08-01) -
Lantus, the first peakless basal insulin analogue: 10 years of clinical experience in children and adolescents
by: Tamara Leonidovna Kuraeva
Published: (2014-07-01) -
When basal insulin is not enough: successful strategies for insulin intensification in patients with type 2 diabetes mellitus
by: Elena V. Buryukova, et al.
Published: (2017-12-01) -
Growth Optimization of Arthrospira platensis SPKY1 for Insulin Production
by: K. Yuvarani, et al.
Published: (2025-06-01)